DARA BioSciences, Inc. (DARA BioSciences), formerly Point therapeutics, Inc. is a development stage pharmaceutical company engaged in the acquisition of therapeutic molecules and medical technologies from third parties, which the company advances its clinical development for later sale to pharmaceutical and biotechnology companies. The company develops and commercializes pharmaceutical products to treat diseases with unmet medical solutions. DARA turned its focus on therapeutic development efforts of small molecules from preclinical development through phase 2 clinical trials. Currently, the company runs two development programs namely, KRN5500 and DB959 for neuropathic pain in cancer patients and, type 2 diabetes respectively. On 12 Feb 2008, DARA completed its merger transaction with Point Therapeutics, Inc., where DP Acquisition Corp. (a wholly owned subsidiary of Point Therapeutics, Inc.) merged into DARA BioSciences, Inc. The company is headquartered in North Carolina, the US.